TITLE

Statin-Associated Polymyositis Following Omeprazole Treatment

AUTHOR(S)
Kanth, Rajan; Shah, Milind S.; Flores, Rafael Medina
PUB. DATE
June 2013
SOURCE
Clinical Medicine & Research;Jun2013, Vol. 11 Issue 2, p91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Statins are an extensively used class of drugs, and myopathy is an uncommon, but well-described side effect of statin therapy. Inflammatory myopathies, including polymyositis, dermatomyositis, and necrotizing autoimmune myopathy, are even more rare, but debilitating, side effects of statin therapy that are characterized by the persistence of symptoms even after discontinuation of the drug. It is important to differentiate statin-associated inflammatory myopathies from other self-limited myopathies, as the disease often requires multiple immunosuppressive therapies. Drug interactions increase the risk of statin-associated toxic myopathy, but no risk factors for statin-associated inflammatory myopathies have been established. Here we describe the case of a man, age 59 years, who had been treated with a combination of atorvastatin and gemfibrozil for approximately 5 years and developed polymyositis after treatment with omeprazole for 7 months. Symptoms did not resolve after discontinuation of the atorvastatin, gemfibrozil, and omeprazole. The patient was treated with prednisone and methotrexate followed by intravenous immunoglobulin, which resulted in normalization of creatinine kinase levels and resolution of symptoms after 14 weeks. It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only.
ACCESSION #
88883694

 

Related Articles

  • ATHEROMA: High-dose atorvastatin associated with reduction in USPIO-defined inflammation. Raible, Eric // Cardiology Today;Jun2009, Vol. 12 Issue 6, p6 

    The article discusses research which revealed that high-dose atorvastatin was associated with a reduction in carotid lesion inflammation as defined by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging (MRI).

  • Niacin Beats Ezetimibe Head to Head. Elliott, William T. // Internal Medicine Alert;1/15/2010 Supplement 1, p1 

    The article discusses several studies on the impact of statins and niacin on high-density lipoprotein cholesterol (HDL-C), the role of omeprazole on the efficacy of clopidogrel, and the effect of darbepoetin on the risk of stroke in the U.S.

  • Atorvastatin/gemfibrozil/omeprazole interaction.  // Reactions Weekly;7/20/2013, Issue 1462, p12 

    The article presents a case study of a 59-year-old man who developed statin-associated polymyositis possibly following an interaction of atorvastatin with gemfibrozil and/or omeprazole.

  • Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Clark, David W. J.; Strandell, Johanna // European Journal of Clinical Pharmacology;Jun2006, Vol. 62 Issue 6, p473 

    Objective: Polymyositis occurring in patients treated with omeprazole has been signalled as a possible adverse drug reaction (ADR) by the New Zealand Intensive Medicines Monitoring Programme (IMMP) and the WHO Collaborating Centre for International Drug Monitoring: the Uppsala Monitoring Centre...

  • Interaction between Several Medicines and Statins. Fujino, Hideki; Saito, Tsuyoshi; Tsunenari, Yoshihiko; Kojima, Junji // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Mar2003, Vol. 53 Issue 3, p145 

    Describes in vitro experiments using human hepatic microsomes to gain a better understanding of drug-drug interaction between various medicinal substances and statins. Metabolic clearance of atorvastatin; Negligibility of the metabolic inhibition of pitavastatin.

  • AHA: beware of drug interactions with statins, CV therapies.  // Reactions Weekly;10/29/2016, Vol. 1625 Issue 1, p7 

    The article discusses the interactions between statins and other cardiovascular (CV) therapies according to the non-profit organization American Heart Association.

  • Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. Paul, Friedemann; Waiczies, Sonia; Wuerfel, Jens; Bellmann-Strobl, Judith; Dörr, Jan; Waiczies, Helmar; Haertle, Mareile; Wernecke, Klaus D.; Volk, Hans-Dieter; Aktas, Orhan; Zipp, Frauke // PLoS Clinical Trials;Apr2008, Vol. 5 Issue 4, Special section p1 

    Background: Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS. Methodology/Principal Findings: Safety, tolerability and effects on disease activity of atorvastatin given alone or in combination with...

  • Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness.  // Journal of Cardiovascular Magnetic Resonance (BioMed Central);2011, Vol. 13 Issue 1, p37 

    The article presents a study focusing on carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance (CMR). It states that during the study six month statin therapy in patients with carotid plaque led to reduced plaque volume by 3T CMR, however...

  • CARDIOVASCULAR MEDICINE NEWSBRIEFS.  // DukeMedicine HealthNews;Feb2012, Vol. 18 Issue 2, p3 

    The article offers news briefs related to cardiovascular medicine. A study on two cholesterol-lowering statin regimens that cause coronary artery disease to regress in some patients has been found. It shows research on percutaneous coronary intervention (PCI) patients. The safety of using of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics